Blocking CD47 interactions was a potent antitumor therapy for NSCLC. Cells resist death by increasing autophagy; simultaneously inhibiting autophagy provided a synergistic antitumor effect, providing a scientific basis for enhancing the efficacy of immune checkpoint inhibitors.
Tumor-infiltrating lymphocytes contain γδ T cells. In early-stage SCC tumors, γδ T cells had antitumor properties, such as production of IFNγ. However, clinically advanced tumors contained many more γδ T cells that produced IL-17 and promoted tumor growth.
The identification of neoepitopes expressed by tumors will aid the effectiveness of antitumor therapies. Four classes of posttranslationally modified tumor neoantigens were identified on primary tumors. Healthy donors had detectable natural immunity to a subset of these.